What Researchers Did
The researchers looked back at medical records from 58 people with severe blocked blood flow in the legs to compare outcomes for those who had repeated hyperbaric oxygen therapy (HBOT) and those who did not.
What They Found
In this retrospective study of 58 patients with chronic limb-threatening ischemia who did not have revascularization, repeated HBOT at 2.8 atm of oxygen was associated with fewer major adverse events and fewer major limb amputations. The average age was 71 years, 67% had diabetes and 43% were on hemodialysis, with average follow-up of 4.3 years. Overall survival was 84.5% at 1 year and 81.0% at 3 years. In the statistical analysis, HBOT was an independent predictor of no major adverse events (odds ratio 0.05, p less than 0.001) and of avoiding major limb amputation (odds ratio 0.04, p equal to 0.003). Higher body mass index, good nutrition and a better ankle-brachial index were also independent predictors.
Canadian Relevance
No direct Canadian connection identified.
Study Limitations
This was a retrospective review, and the control group was made up of patients who could not continue HBOT plus historical controls, so the groups may have differed in ways that affected the results.